European Congress of Pathology (ECP)

ECP 2023

35th European Congress of Pathology (ECP) 2023

9 - 13 September 2023
Dublin, Ireland 


Driving diagnostic certainty - For Life-Changing Decisions in Oncology

The motto for ECP 2023 is “Pathology – a bridge between Science and Medicine” acknowledges the significant changes that practicing pathologists have made and continue to make to their daily practice to ensure that new beneficial diagnostic and technological advancements are embraced and integrated into everyday practice for the benefit of all patients. The meeting will reflect the extremely dynamic development in the field of pathology and update on these advancements through the excellent programme prepared by the ESP working groups, ESP-affiliated Societies, Education and Trainee Subcommittees.

Roche, as a leader in oncology and personalized healthcare, has been a long-standing partner of the Pathology community and will be a premium sponsor for this year’s meeting and will have multiple activities during the congress. 



Join us

Roche booth

9  -  13 September 2023
Dublin, Ireland   

DRIVING DIAGNOSTIC CERTAINTY- For Life-Changing Decisions in Oncology

We have a strong belief that throughout each person's journey, diagnostic testing supports a clinician in decisions that lead to better outcomes. Our exhibition this year will focus on highlighting our products and solutions that help clinicians meet the medical needs of patients along their cancer journey.

Our medical and product experts will be available to discuss the fit of our portfolio in terms of addressing a medical need or pain point for patients and healthcare professionals.

Our exhibition at ECP will highlight innovation in our portfolio across technologies in diagnostics and information solutions , including Pathology Lab solutions, High medical value assays, molecular tests, foundation medicine, and more.


Join us
Brain dates

We are hosting sessions on the following topics at the Roche booth # 41 at the Convention Centre Dublin.
Click on the link below to learn more about these sessions and register to attend.
Each session is limited to 5 attendees.

Link to register

Topic of the Braindates and Hosts

Sunday, 10 September 2023

Roche booth # 41

9:30 - 10:00 am
The role of the pathologist for successful CGP testinge
Sotirios Lakis
EU Medical Director at Foundation Medicine (Penzberg) , MD, PhD anatomical pathologist with 10 years of experience in Translational Research, and Cancer Diagnostics.

4:45 - 5:15 pm
HER2 low: what is clinical validity? What is new, what is not?
Emilia Andersson
Pathologists and Oncology lead Medical and Government affairs, EMEA-LATAM at Roche

Monday, 11 September 2023

Roche booth # 41

9:30 - 10:00 am
The value of bioinformatics in CGP testing and comparison data of 2 commercially available tissue-based CGP solutions (ECP Poster)
Thomas Wieland
Sr. Director, International Bioinformatics & Technology at Foundation Medicine
(1st author and presenter of our poster at ECP)

4:45 - 5:15 pm
The value of Liquid Biopsy as a complementary approach to tissue. Liquid and/or Tissue ? A Patient centric approach
Gilles Erb
Global Scientific Director Integrated Healthcare Solutions, Personalized Medicine Oncology at Roche

Tuesday, 12 September 2023

Roche booth # 41

9:30 - 10:00 am
Digital Pathology as a lever for precision oncology: What is the best approach to bring the value of AI into the Pathology practice?
Michael Rivers
Lifecycle Leader, Digital Pathology at Roche
Marta Cañamero
Medical lead for Digital Pathology, Medical and Government affairs, EMEA-LATAM at Roche

4:45 - 5:15 pm
Collaboration and Co-creation: innovative and clinically meaningful study idea? (Exchange on potential study concept and idea that would impact future clinical practice)
Gilles Erb
Global Scientific Director Integrated Healthcare Solutions, Personalized Medicine Oncology at Roche

Meet the speakers

Emilia Andersson

Emilia Andersson, MD, PhD

Pathologist, Oncology lead Medical & Government affairs Roche Dia 

Emilia Andersson is the oncology lead at Roche Medical and Governmental Affairs team in the EMEA-LATAM region. She is a certified pathologist in surgical pathology and cytopathology from Karolinska University Hospital. Her thesis on biomarkers in tumor immunology led her to Roche Pharma where she worked with exploration of the tumor microenvironment and development of new biomarker analysis in clinical studies including multiplex analyses and digital algorithms. Before rejoining Roche she was the Medical Director for Pathology at Unilabs in Sweden, directing a large group of about 50 pathologists and 200 staff, implementing digital pathology for primary diagnosis on a large scale. She was also leader of the Unilabs international pathology expert team. Emilia is the former president of the Swedish board of pathologists and was heavily involved in implementing national guidelines for digital pathology and pre-analysis. She is still practicing clinical pathology as a consultant.

Magali Lacroix-Triki

Magali Lacroix-Triki, MD, PhD

Pathologist, Institut Gustave Roussy

Dr Magali Lacroix-Triki, MD, PhD, President of the French Division of the International Academy of Pathology (AIP-DF), is an expert breast pathologist, with a strong involvement in translational research. She is the referent pathologist of several multicentric national and international breast clinical trials in the Unicancer frame. She is also the referent pathologist of the Unicancer Personalized Medicine Committee, and was the coordinator of the French GEFPICS group, comprising breast pathologists all over France and Belgium, until November 2021. She joined Gustave Roussy Cancer Campus in December 2015 (Pathology Department and Pr Fabrice ANDRE INSERM U981 Research Unit).

Nadim Habib

Nadim Habib, Ass Prof

Health economics, Nova School of Business and Economics

Nadim is currently a lecturer at Nova School of Business and Economics where he teaches strategy and innovation for the Masters, MBA and Executive Education programs. He is also a member of the Strategic Board of the Research Institute for Medicines at the University of Lisbon, and Coordinator of the Health Care Policy Think Tank at SEDES where he has coordinated and authored several studies on healthcare policy and management. He additionally works as a consultant and speaker in the field of organizational agility and high-performance organizations, with a special emphasis on healthcare delivery and performance.

Federico Rojo Todo

Federico Rojo Todo, MD, PhD

Director Patologia Molecular Pathologist Fundacion Jimenez Diaz

Dr. Federico Rojo (MD, PhD) is a Senior Physician in Pathology at Fundación Jiménez Díaz (FJD) University Hospital in Madrid since 2007, where he is also the leader of the Molecular Pathology Laboratory and the Head of the Pathology Department. He is the Head of the Research Breast Cancer Group, Coordinator of the Cancer Research Area and Scientific Director of the Biobank at the Biomedical Research Institute of the same institution, IIS-FJD. Since 2010, he is also the president of the pathologist group at Spanish Breast Cancer Research Group, GEICAM, and member of GEICAM´s Steering Committee. In 2017-19, Dr Rojo developed the role of Secretary of the Spanish Society of Pathology, SEAP.  He completed his training as a medical resident in Pathology between 1995 and 1998 in Hospital Vall d’Hebron, Barcelona, where he also conducted his PhD in Molecular Biology in Cancer for 7 years in the oncology group, led by Dr. Baselga. He enjoyed an international stay during this period at the MD Anderson Cancer Center in Texas.

Umberto Malapelle

Umberto Malapelle, PhD

Researcher in Anatomic Pathology, Department of Public Health, University of Naples “Federico II” 

Dr. Umberto Malapelle is the Chief of Predictive Molecular Pathology Laboratory, Department of Public Health of University Federico II of Naples and the Scientific Secretary of the International Society of Liquid Biopsy. His main research interest is in the field of genomic biomarkers validation and testing for predictive information in the field of lung cancer, metastatic colorectal cancer, melanoma and gastrointestinal stromal tumor. Moreover, he has developed skills in tailoring Next Generation Assays for a number of different applications with a special focus on the simultaneously detection of clinical relevant alterations (i.e. EGFR mutations, ALK translocation, PD–L1 expression) in the routine setting including handling of different sample types, such as tissues and/or liquid biopsy specimens.

Léon van Kempen

Léon van Kempen, PhD

Head of Laboratory for Molecular Diagnostics, Antwerp University Hospital

Prof. dr. Léon van Kempen is a clinical scientist in molecular pathology and is currently the director of the laboratory for molecular diagnostics at the Antwerp University Hospital, Belgium. He obtained his PhD in molecular pathology from the University of Nijmegen (The Netherlands) and subsequently specialized in molecular diagnostics. He was the Chief Officer of Operations at the Molecular Pathology Center at the Jewish General Hospital (McGill University, Montréal, Canada) and subsequently member of staff at the department of Pathology of the University Medial Center Groningen (UMCG, The Netherlands).  As an expert in molecular diagnostics, was a member of the UMCG MTB and is currently a member of the Belgian national MTB (NCT05058937).

His current research activities can be found here .


Ana Peixoto

Ana Peixoto, PharmD, PhD

Human Genetics Specialist, Portuguese Oncology Institute of Porto

Graduated in Pharmaceutical Sciences from the Faculty of Pharmacy of the University of Porto (1995), with a masters degree in Applied Human Genetics from the Faculty of Sciences of the University of Porto (1998), and a PhD degree in Biomedical Sciences from the School of Medicine and Biomedical Sciences (ICBAS) at the University of Porto (2019). Specialized in Human Genetics dedicated to the molecular diagnosis of hereditary predisposition to cancer and acquired genetic alterations relevant for diagnosis or prognosis, or predictive of response to targeted therapies, in the Department of Laboratory Genetics of the Portuguese Institute of Oncology of Porto. Author/co-author of 68 scientific publications in international indexed journals.

Dearbhaile Collins

Dearbhaile Collins, MBBCh BAO MA PhD IMRCS MRCPI

Cork University Hospital

Dearbhaile is an Irish trained Consultant Medical Oncologist with speciality interest in lung cancer and gynecological malignancies but also treats a variety of other cancers. She has both a PhD in translational oncology and MA in Medical Ethics and Law. She has extensive experience in both surgical and medical oncology with numerous publications, presentations, grants and awards. She is a recipient of the Irish Cancer Society Clinician Research Leadership Award 2020 that ring fences protected academic time for her to pursue her translational research interests. 

Dearbhaile currently works as a Consultant Medical Oncologist at Cork University Hospital and Kerry University Hospital, and she is a Senior Lecturer in Cancer Research with University College Cork.


Paula Toro

Paula Toro

Pathologist, Roche Diagnostics International Ltd.

Pathologist and Ph.D., current Medical Affairs Director for Breast Cancer in Roche Diagnostics Solutions. Member of the European Society of Pathology and the Spanish Society of Pathology. Special emphasis on bringing Companion Diagnostic into clinical practice and pathologists training. Joined Roche in 2016.